The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
14 Apr 2021
14 Apr 2021
Historique:
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
22
4
2021
Statut:
epublish
Résumé
The emergence of SARS-CoV-2 variants with mutations in key antibody epitopes has raised concerns that antigenic evolution will erode immunity. The susceptibility of immunity to viral evolution is shaped in part by the breadth of epitopes targeted. Here we compare the specificity of antibodies elicited by the mRNA-1273 vaccine versus natural infection. The neutralizing activity of vaccine-elicited antibodies is even more focused on the spike receptor-binding domain (RBD) than for infection-elicited antibodies. However, within the RBD, binding of vaccine-elicited antibodies is more broadly distributed across epitopes than for infection-elicited antibodies. This greater binding breadth means single RBD mutations have less impact on neutralization by vaccine sera than convalescent sera. Therefore, antibody immunity acquired by different means may have differing susceptibility to erosion by viral evolution. Deep mutational scanning shows the mRNA-1273 RBD-binding antibody response is less affected by single viral mutations than the infection response.
Identifiants
pubmed: 33880474
doi: 10.1101/2021.04.14.439844
pmc: PMC8057239
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127893
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2
pubmed: 33789085
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
J Virol. 2021 Mar 1;95(10):
pubmed: 33649194
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Am J Epidemiol. 1986 May;123(5):862-8
pubmed: 3008551
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
PLoS Pathog. 2021 Apr 8;17(4):e1009453
pubmed: 33831132
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
J Open Source Softw. 2020;5(52):
pubmed: 34189395
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7550-E7558
pubmed: 30037990
Nat Commun. 2020 Sep 1;11(1):4378
pubmed: 32873791
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2021 May;593(7857):130-135
pubmed: 33684923